Update shared on10 Sep 2025
Fair value Decreased 14%The downward revision in Sutro Biopharma’s price target reflects worsening net profit margin and deeper negative revenue growth forecasts, with fair value decreasing from $3.11 to $2.69.
What's in the News
- Sutro Biopharma entered a collaboration with the FDA to co-develop reference materials and improve regulatory standards for ADC drug development, leveraging Sutro's XpressCF technology and FDA's analytical capabilities.
- The company received notification from NASDAQ of non-compliance with the $1.00 minimum bid price requirement, with a 180-day window to regain compliance or face potential delisting; management may implement a reverse stock split if necessary.
- Sutro Biopharma was dropped from numerous Russell value and small cap indexes, including Russell 2000, Russell 2500, Russell 3000, and related value sub-indexes.
- The stock was simultaneously added to the Russell Microcap Growth Index and Russell 3000E Growth Index.
Valuation Changes
Summary of Valuation Changes for Sutro Biopharma
- The Consensus Analyst Price Target has significantly fallen from $3.11 to $2.69.
- The Net Profit Margin for Sutro Biopharma has significantly fallen from 16.06% to 14.17%.
- The Consensus Revenue Growth forecasts for Sutro Biopharma has fallen from -20.0% per annum to -21.6% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.